Search “Ozempic price India” and you'll get numbers ranging from ₹3,500 to ₹45,000. They're not all wrong — they're measuring different things. Here's the actual breakdown so you can plan a budget without getting blindsided.

1. The medication itself

As of mid-2026, the three GLP-1 receptor agonists most commonly dispensed in India are:

  • Semaglutide injection (Ozempic, Rybelsus is the oral version): around ₹7,000–₹15,000 per month depending on dose and brand.
  • Semaglutide for chronic weight management (Wegovy, approved separately): typically ₹17,000–₹26,000 per month.
  • Tirzepatide (Mounjaro, dual-agonist): around ₹14,000–₹28,000 per month depending on dose.

Prices change with dose escalation. You start low (e.g. 0.25 mg semaglutide weekly) and step up monthly to a clinically effective dose. The first 2–3 months are typically cheaper than the maintenance dose.

2. What's not included in a sticker price

The medication is one cost. A real treatment plan also includes:

  • Initial doctor consultation— legally required before any Rx; typically ₹800–₹2,000.
  • Monthly follow-up consult— for dose adjustment and refill: ₹500–₹1,500 each, or included in a subscription.
  • Baseline labs— HbA1c, lipid panel, basic metabolic profile: ₹1,500–₹3,000 one-time.
  • Cold-chain delivery— mandatory for refrigerated pens; in many cities still chargeable, around ₹200–₹500 per shipment.
  • GST— 12% on medication, 18% on consultations.

Bought stand-alone, that adds up to ₹3,000–₹5,000per month beyond the medication itself.

3. The ZIVOLABS subscription model

Our subscription bundles everything into a single monthly amount. Patients on a starter plan pay:

Starter month (first month)
₹7,999
Introductory first-month price — includes consultation, baseline labs, medication, free cold-chain delivery, weekly check-ins, and unlimited doctor messaging. Renews at ₹9,999/month from month 2.

Subsequent months scale with dose — from ₹7,500 at the lowest titration to ₹19,500 at full dose, all-inclusive. No separate consultation, delivery, or admin fee.

4. How this compares to the US

In the United States, semaglutide without insurance costs roughly USD 1,000 per month — about ₹83,000 at current exchange. Tirzepatide is even higher. Indian patients pay between 1/6th and 1/10th of US sticker prices, even at the maintenance dose.

Some of that gap is local manufacturing under voluntary licence, some is regulatory price control through the National Pharmaceutical Pricing Authority. The result: an internationally-equivalent therapy at a price that's manageable for middle-income households.

5. Hidden costs to plan for

  • Lifestyle support.A protein-rich diet is non-negotiable; you'll likely spend ₹1,500–₹3,000 more per month on protein-rich groceries (dal, paneer, eggs, fish, supplements).
  • Resistance training. Gym membership or home equipment to protect muscle mass while losing weight.
  • Time off the medication.If you pause for 2–3 months (travel, surgery, illness), restart usually requires re-titration — a slight cost bump in those early restart months.

6. Is it worth it?

The clinical evidence is solid: a meaningful fraction of people who stay on GLP-1 therapy for 12+ months lose 15–20% of body weight. For someone at 95 kg, that's 14–19 kg. Most importantly, it reduces the risk of every weight-related complication: type 2 diabetes, fatty liver, hypertension, sleep apnoea, joint disease.

For Indians with abdominal obesity (waist > 90 cm for men, >80 cm for women) and a metabolic risk factor, the cost-to-benefit is genuinely favourable compared to managing those conditions separately for the next two decades.

The 5-minute qualification check below tells you whether your BMI and history make you a clinical fit — no commitment, no card needed.

Sources
  • National Pharmaceutical Pricing Authority (NPPA) ceiling-price notifications, 2025–2026.
  • Wholesale price catalogues from licensed distributors in Maharashtra and Karnataka.
  • US Medicare Part D 2025 retail-price data, KFF analysis.